{"entity":{"id":"dr-reddys","kind":"company","name":"Dr. Reddy's Laboratories","aka":[],"tldr":"The Hyderabad generics maker that launched the world's first rituximab biosimilar in 2007 and now sells oncology generics and biosimilars in India, the US and Europe.","summary":"Dr. Reddy's was founded in 1984 by Kallam Anji Reddy and is listed on the NSE, BSE and NYSE. It was an early mover in biosimilars: its rituximab, Reditux, was approved in India in 2007, the first rituximab biosimilar anywhere, and its EU rituximab (Ituxredi) was authorised in September 2024 at a price several times below the reference brand. The company is a major supplier of oncology generics (abiraterone, bortezomib, azacitidine, decitabine and many injectables) to the US and India, and its oncology-focused subsidiary Aurigene runs discovery and clinical programmes. Dr. Reddy's also in-licenses innovative oncology products for India.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Dr._Reddy's_Laboratories","links":[{"label":"Official website","url":"https://www.drreddys.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","chemotherapy"],"technologies":["monoclonal-antibody"],"targets":["cd20"],"drugs":["rituximab","abiraterone","bortezomib","azacitidine"],"companies":["aurigene"],"institutions":[],"pathways":[],"terms":["biosimilar"],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hyderabad","country":"IN","companyType":"pharma","website":"https://www.drreddys.com","ticker":"RDY","founded":1984,"investors":[],"funding":[]},"route":"/companies/dr-reddys/","neighbours":{"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"biosimilar-manufacturing","kind":"technology","name":"Biosimilar manufacturing and comparability","route":"/technologies/biosimilar-manufacturing/"},{"id":"sterile-injectable-generics-manufacturing","kind":"technology","name":"Generic sterile injectables (the 2023 platinum shortage)","route":"/technologies/sterile-injectable-generics-manufacturing/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"oral-solid-dose-manufacturing","kind":"technology","name":"Oral solid dose manufacturing (tablets and capsules)","route":"/technologies/oral-solid-dose-manufacturing/"},{"id":"small-molecule-api-synthesis","kind":"technology","name":"Small-molecule API synthesis","route":"/technologies/small-molecule-api-synthesis/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"aurigene","kind":"company","name":"Aurigene Oncology","route":"/companies/aurigene/"}],"term":[{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}